Summary: This is a published study protocol, not a results paper. It describes a planned 52-week double-blind randomised trial in 105 overweight or obese adults with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), comparing semaglutide plus empagliflozin against each drug as monotherapy. The primary outcomes will be changes in controlled attenuation parameter, free fatty acid and glucagon. No efficacy or safety findings are reported, because none have been generated yet.
PICO Summary
| Element | Detail |
|---|---|
| Population | Planned n = 105 overweight or obese adults with NAFLD and type 2 diabetes; 52-week double-blind, randomised, parallel-group, active-controlled trial; conducted in China (registered ChiCTR2300070674). |
| Intervention | Semaglutide (GLP-1 receptor agonist) plus empagliflozin (SGLT-2 inhibitor) combination arm. |
| Comparison | Two active monotherapy arms: semaglutide alone and empagliflozin alone (three arms in total, with the 105 participants distributed across them). |
| Outcome | No results reported (protocol only). Pre-specified primary outcome: change from baseline to week 52 in controlled attenuation parameter, free fatty acid and glucagon. Secondary outcomes include liver stiffness, liver enzymes, blood glucose, lipids, renal function, fibrosis scores (NFS, FIB-4) and HOMA-IR. No effect estimates, confidence intervals, p values, ARR or NNT are available. |
Expert Commentary
This paper should be read for what it is: a design document, not evidence of benefit. It sets out a reasonable and clinically relevant question, since combining a GLP-1 receptor agonist with an SGLT-2 inhibitor is increasingly common in type 2 diabetes, and whether the pairing adds anything for hepatic steatosis beyond either drug alone remains genuinely uncertain. The double-blind, active-controlled design is a strength and the use of controlled attenuation parameter and liver stiffness avoids the burden of repeated biopsy. The dominant limitation is simply that no outcomes exist yet; a planned sample of 105 split across three arms is also modest, which will limit power for between-arm comparisons and for the safety signals that matter most when two agents are combined. The verdict is therefore that no efficacy claim can be drawn from this publication, and any suggestion that the combination improves NAFLD is premature. Can I use this with my patients? Not yet. It changes nothing at the bedside today and should not be cited as support for combination therapy in fatty liver. For a patient with NAFLD and type 2 diabetes, current practice still rests on weight loss, glycaemic control and existing outcome trials. The directive is to register the result, wait for the 52-week readout, and judge the combination on the reported effect sizes rather than on its rationale.
References
Lin YH, Zhang ZJ, Zhong JQ, Wang ZY, Peng YT, Lin YM, Zhang HP, Tian JQ. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial. PLoS One. 2024;19(5):e0302155. doi:10.1371/journal.pone.0302155
